866-997-4948(US-Canada Toll Free)

Global Healthcare CMO Market: Trends & Opportunities (2015-2020)

Published By :

Daedal Research

Published Date : Jan 2016

Category :

Pharmaceutical

No. of Pages : 55 Pages

This report named “Global Healthcare CMO Market: Trends & Opportunities (2015-2020)”, analyses the growth and sizing of global healthcare CMO market and its segments. This report provides the analysis of global healthcare CMO market by value and by segment.

The analysis of global medical device CMO market is done by value, by players and by cost structure and analysis of global pharmaceutical CMO is done by value and by segments. The global pharmaceutical CMO market by segments is analyzed in detail by providing analysis of each of its segment.

This report includes the analysis of global active pharmaceutical ingredient CMO market by value and analysis of finished dosage formulation CMO market by value, by revenue structure, by geographical approach and by dosage formulation.

This report also provides the analysis of global pharmaceutical CDMO market. This analysis includes the global pharmaceutical CDMO market by value, by players and by geography. The regional analysis of global pharmaceutical CDMO market is also done in this report. The regions included are United States of America, Europe, China and India.

This report also includes the growth drivers, market trends and challenges faced by global healthcare CMO market. Company profiling of major players of healthcare CMO industry is also done in this report. The companies included are Catalent Pharma Solution, Recipharm and Aurobindo Pharma Ltd. Business overview, financial overview and business strategies for each company is provided.

Company Coverage

  • Catalent Pharma Solution
  • Recipharm
  • Aurobindo Pharma Limited

Executive Summary

Contract manufacturing is a type of outsourcing in which a firm contacts with a third party (contract manufacturing organization) for the manufacturing of components of its product or whole of its product. A contract manufacturing organization (CMO) undertakes the production of product(s) under the brand name of another firm.

A big or a mid-sized firm opt for a CMO mainly for two reasons, either it wants to shift (or reduce) its cost and focus to its core activities, or the manufacturing of its products require special or expert handing. CMOs provide independent manufacturing services in healthcare sector also. Healthcare CMOs can be segmented into pharmaceutical CMOs and medical device CMOs. After the discovery of chemical formula of a new drug, the pharmaceutical CMOs are given the task of manufacturing it into a whole product, so that the pharmaceutical companies are able to sell it into the market under their brand name. Services offered by pharmaceutical CMOs can be divided into two main activities: primary manufacturing (Active Pharmaceutical Ingredients) and secondary manufacturing (Finished Dosage Formulation). Contract manufacturing for medical devices is one of the fastest growing segments of the medical device industry, as companies are in the race to bring new devices to the market.

From last few years, many pharmaceutical CMOs have included development part into their activities, apart from manufacturing of drugs and they are called contract development & manufacturing organizations (CDMOs). The market for pharmaceutical CMOs and CDMOs can neither be taken as same, nor be taken as completely distinct from each other. Also, these two markets cannot be combined together, as it will exaggerate the global pharmaceutical CMO market.

The global healthcare CMO market has recorded a continuous growth since last few years and is expected to follow the same trend in coming years. The main driving factors for this growth are rise in global pharmaceutical industry, increased need for outsourcing, increased approvals and outsourcing of NMEs, innovations and increased regulatory pressure on quality. Yet there are some challenges, which healthcare CMO industry faces, such as fragmented nature of market, less preference for outsourcing of profitable and biological drugs by big pharmaceutical companies.

Table of Content

1. Executive Summary

2. Introduction

2.1 Healthcare CMOs
Table 1: Healthcare CMO Market by Segments
2.1.1 Pharmaceutical CMOs
Active Pharmaceutical Ingredients (API)
Finished Dosage Formulations (FDF)
2.1.2 Medical Device CMOs
2.2 Pharmaceutical Outsourcing
Table 2: Pharmaceutical Outsourcing by Segments
OTC Contracts and Nutraceuticals
Contract Manufacturing of Bulk Drugs & Dosage Forms
Contract Research & Development
Contract Packaging
2.3 Pharmaceutical CMOs v/s CDMOs
Table 3: Value Chain of a Drug

3. Global Healthcare CMO Market: An Analysis
3.1 Global Healthcare CMO Market: Sizing and Growth
3.1.1 Global Healthcare CMO Market by Value
Table 4: Global Healthcare CMO Market by Value; 2012-2014 (US$ Billion)
Table 5: Global Healthcare CMO Market by Value; 2015-2020 (US$ Billion)
3.1.2 Global Healthcare CMO Market by Segments
Table 6: Global Healthcare CMO Market by Segments; 2014
3.2 Global Medical Device CMO Market: Sizing and Growth
3.2.1 Global Medical Device CMO Market by Value
Table 7: Global Medical Device CMO Market by Value; 2012-2014 (US$ Billion)
Table 8: Global Medical Device CMO Market by Value; 2015-2020 (US$ Billion)
3.2.2 Global Medical Device CMO Market by Players
Table 9: Global Medical Device CMO Market by Players; 2014E
3.2.3 Global Medical Device CMO Market by Cost Structure
Table 10: Global Medical Device CMO Market by Cost Structure; 2014
3.3 Global Pharmaceutical CMO Market: Sizing and Growth
3.3.1 Global Pharmaceutical CMO Market by Value
Table 11: Global Pharmaceutical CMO Market by Value; 2012-2014 (US$ Billion)
Table 12: Global Pharmaceutical CMO Market by Value; 2015-2020 (US$ Billion)
3.3.2 Global Pharmaceutical CMO Market by Segments
Table 13: Global Pharmaceutical CMO Market by Segments; 2014
3.4 Global Active Pharmaceutical Ingredient (API) CMO Market: Sizing and Growth
3.4.1 Global Active Pharmaceutical Ingredient CMO Market by Value
Table 14: Global Active Pharmaceutical Ingredient CMO Market by Value;
2013-2020E (US$ Billion)
3.5 Global Finished Dosage Formulation (FDF) CMO Market: Sizing and Growth
3.5.1 Global Finished Dosage Formulation CMO Market by Value
Table 15: Global Finished Dosage Formulation CMO Market by Value; 2009-2014
(US$ Billion)
Table 16: Global Finished Dosage Formulation CMO Market by Value; 2015-2020
(US$ Billion)
3.5.2 Global Finished Dosage Formulation CMO Market by Revenue Structure
Table 17: Global Finished Dosage Formulation CMO Market by Revenue Structure; 2014
3.5.3 Global Finished Dosage Formulation CMO Market by Geographical Approach
Table 18: Global Finished Dosage Formulation CMO Market by Geographical Approach; 2014
3.5.4 Global Finished Dosage Formulation CMO Market by Dose Formulation
Table 19: Global Finished Dosage Formulation CMO Market by Dose Formulation; 2014

4. Global Pharmaceutical CDMO Market: An Analysis
4.1 Global Pharmaceutical CDMO Market: Sizing and Growth
4.1.1 Global Pharmaceutical CDMO Market by Value
Table 20: Global Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Table 21: Global Pharmaceutical CDMO Market by Value; 2015-2019 (US$ Billion)
4.1.2 Global Pharmaceutical CDMO Market by Geography
Market Share by Geography
Table 22: Global Pharmaceutical CDMO Market Share by Geography; 2014
Market Growth by Geography
Table 23: Global Pharmaceutical CDMO Market Growth by Geography;
2011-2015 (CAGR, %)
4.1.3 Global Pharmaceutical CDMO Market by Players
By Sales Range
Table 24: Global Pharmaceutical CDMO Market Players by Sales Range; 2014 (US$ Million)
By Geography
Table 25: Global Pharmaceutical CDMO Market Players by Geography; 2014
4.2 Global Pharmaceutical CDMO Market: A Regional Analysis
4.2.1 USA’s Pharmaceutical CDMO Market by Value
Table 26: USA’s Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Table 27: USA’s Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
4.2.2 European Pharmaceutical CDMO Market by Value
Table 28: European Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Table 29: European Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
4.2.3 China’s Pharmaceutical CDMO Market by Value
Table 30: China’s Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Table 31: China’s Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
4.2.4 Indian Pharmaceutical CDMO Market by Value
Table 32: Indian Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Table 33: Indian Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Growth in Global Pharmaceutical Industry
Table 34: Global Pharmaceutical Industry; 2007-2014 (US$ Billion)
5.1.2 Drug Plants Divested by Big Pharmaceutical Companies
Table 35: Drug Plants Divested; 2000-2013 (avg.)
5.1.3 Outsourced Production
Table 36: Outsourced Production; 2014
5.1.4 NMEs Requiring Special Handling
Table 37: NME’s Approved and Outsourced; 2010-2014
5.2 Challenges
5.2.1 Highly Fragmented Market
5.2.2 Less Preference for Outsourcing of Profitable Drugs
5.2.3 Manufacturing of Biological Drugs Less Outsourced
5.2.4 Investment in Own Production Facilities by Pharmaceutical Companies
Table 38: Investment in Own Production Facilities by Pharmaceutical Companies; 2010-2014 (US$ Million)
5.3 Market Trends
5.3.1 Increased reliance on CMO/CDMO services
5.3.2 Innovation
5.3.3 Increased Regulatory Pressure on Quality
5.3.4 Change in Cost Base of Big Pharmaceutical Companies
5.3.5 Dosage Forms likely to be outsourced
Table 39: Dosage Forms likely to be outsourced; 2014-2015

6. Competitive Landscape
Table A: Financial Comparison of Players in Global Healthcare CMO Market; 2014

7. Company Profiles
7.1 Catalent Pharma Solutions Inc.
7.1.1 Business Overview
7.1.2 Financial Overview
Table 40: Catalent Pharma Solutions, Inc. Net Revenue; 2009-2014 (US$ Million)
Table 41: Catalent Pharma Solutions Inc. Revenue by Segments; 2014
7.1.3 Business Strategies
Expansion
Relationships with Blue Chip Customers
High Operational and Quality Standards
7.2 Recipharm
7.2.1 Business Overview
Table 42: Recipharm Business Overview
7.2.2 Financial Overview
Table 43: Recipharm Net Sales; 2010-2014 (US$ Million)
Table 44: Recipharm Net Sales by Segments; 2014
Table 45: Recipharm Net Sales by Customers; 2014
7.2.3 Business Strategy
Expanding the current customer base
Investment in new technologies or areas with strong growth
Streamlining operations
7.3 Aurobindo Pharma Limited
7.3.1 Business Overview
7.3.2 Financial Overview
Table 46: Aurobindo Pharma Ltd. Revenue; 2010-2014 (US$ Million)
Table 47: Aurobindo Pharma Ltd. Revenue by Segments; 2014
Table 48: Aurobindo Pharma Ltd. Revenue by Geography
7.3.3 Business Strategy
Plans for 2015-2016
New Initiative

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Muckle-Wells Syndrome Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    Muckle-Wells Syndrome (MWS) is a rare, genetic autosomal disease which leads to urticaria, sensorineural deafness, and also leads to amyloidosis. The disease is mainly caused due to mutation of CIAS1 gene, that leads to increased production of interleukin 1B. Due to interaction of IL1B and skin receptors, the inflammation occurs, which leads to fever and rashes. The common symptoms include fevers, chills, deafness, arthritis, and recurrent urtica...

  • Lymphoblastic Lymphoma Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020

    Lymphobalstic lymphoma is also known as non-hodgkin lymphoma a type of cancer that primarily affects lymphatic system. The lymphatic system comprises organs such as the thymus, bone marrow, spleen, and the lymph nodes (or lymph glands). Lymph nodes are connected by a network of tubes called lymphatic vessels that contain lymph fluid and lymphatic tissue is also found in other organs such as skin, lungs and stomach. Prevalence of lymphoblastic lym...

  • Endobronchial Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

    Endobronchial cancer are characterized by small size, slow growth and usually misdiagnosed as asthma or chronic bronchitis due to their common symptoms. These cancers are usually benign and rare. Due to these reasons, they may remain undiagnosed for a long time and lead to serious complications. The term bronchial adenoma encompasses a diverse group of tumors of mucous glands, trachea or bronchi. Common symptoms of endobronchial cancer include ...